Drugs / Bio-oss
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04433117 | Jun 2020 → Feb 2023 | bone resorption disease, tooth disorder | Mohanad Al-Sabbagh | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01911819 | Dec 2013 → Jun 2016 | — | Loma Linda University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01634308 Comparator | Jun 2010 → Jun 2012 | — | Daewoong Pharmaceutical Co. LTD. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bio-oss | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01911819 ↗ |
| Modality | Other / unclassified | “an inorganic bovine bone xenograft (ABX)” PMID 26185033 ↗ Jul 2015 |